Cue Biopharma (NASDAQ:CUE) VP Sells $32,089.20 in Stock

Cue Biopharma, Inc. (NASDAQ:CUE) VP Michael Vincent Meluzio sold 1,144 shares of the firm’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $28.05, for a total value of $32,089.20. Following the sale, the vice president owned 47,817 shares of the company’s stock, valued at $1,341,266.85. This represents a 2.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Vincent Meluzio also recently made the following trade(s):

• On Thursday, August 13th, Michael Vincent Meluzio sold 5,628 shares of Cue Biopharma stock. The stock was sold at an average price of $30.09, for a total value of $169,346.52.

Cue Biopharma Stock Performance

Shares of NASDAQ CUE traded down $1.96 during midday trading on Friday, reaching $16.71. 106,462 shares of the company’s stock were exchanged, compared to its average volume of 475,957. Cue Biopharma, Inc. has a 52-week low of $4.97 and a 52-week high of $45.50. The business’s fifty day moving average price is $27.36 and its two-hundred day moving average price is $70.48. The stock has a market capitalization of $121.31 million, a PE ratio of -0.62 and a beta of 2.62.

Cue Biopharma (NASDAQ:CUE) last issued its quarterly earnings results on Friday, August 14th. The company reported ($24.14) EPS for the quarter, missing analysts’ consensus estimates of ($1.69) by ($22.45). Cue Biopharma had a negative net margin of 435.83% and a negative return on equity of 620.06%. The business had revenue of $7.88 million during the quarter, compared to analysts’ expectations of $3.00 million. Analysts predict that Cue Biopharma, Inc. will post -21.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on CUE. Wall Street Zen lowered Cue Biopharma from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 26th. Zacks Research raised shares of Cue Biopharma to a “hold” rating in a research report on Monday, September 21st. B. Riley Financial started coverage on shares of Cue Biopharma in a research note on Friday, September 18th. They issued a “buy” rating and a $83.00 price target for the company. Finally, Weiss Ratings cut shares of Cue Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 27th. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Cue Biopharma currently has a consensus rating of “Hold” and an average price target of $83.00.

Institutional Trading of Cue Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of CUE. BlackRock Inc. bought a new position in Cue Biopharma during the 2nd quarter worth approximately $1,824,000. ADAR1 Capital Management LLC bought a new stake in shares of Cue Biopharma in the 2nd quarter valued at approximately $1,742,000. Citadel Advisors LLC increased its holdings in shares of Cue Biopharma by 301.8% in the 2nd quarter. Citadel Advisors LLC now owns 25,633 shares of the company’s stock valued at $809,000 after acquiring an additional 38,333 shares during the last quarter. Texas Capital Bank Wealth Management Services Inc bought a new stake in shares of Cue Biopharma in the 2nd quarter valued at approximately $722,000. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of Cue Biopharma during the 2nd quarter valued at approximately $389,000. Institutional investors and hedge funds own 35.04% of the company’s stock.

Cue Biopharma Company Profile

Cue Biopharma, Inc is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s approach is based on its proprietary Immuno-STAT (Selective Targeting of Antigenic T cells) platform, which is designed to selectively activate and expand disease-specific T cells in the body while potentially reducing the broad immune activation associated with some conventional immunotherapies.

Cue Biopharma’s pipeline includes biologic product candidates intended to target cancer-associated antigens.